C07K 2317/51
Complete heavy chain or fd fragment, i.e. vh + ch1
Official title: Complete heavy chain or Fd fragment, i.e. VH + CH1
C07K2317/51 (Complete heavy chain or fd fragment, i.e. vh + ch1) appears on 1,253 US grants and 2,093 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,253
- Published applications
- 2,093
- Assignees
- 660
- Inventors
- 3,325
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 4 | 2 |
| 2003 | 1 | 3 |
| 2004 | 0 | 5 |
| 2005 | 0 | 6 |
| 2006 | 3 | 4 |
| 2007 | 2 | 10 |
| 2008 | 4 | 8 |
| 2009 | 4 | 29 |
| 2010 | 6 | 31 |
| 2011 | 16 | 43 |
| 2012 | 19 | 44 |
| 2013 | 31 | 73 |
| 2014 | 40 | 107 |
| 2015 | 48 | 120 |
| 2016 | 111 | 222 |
| 2017 | 92 | 214 |
| 2018 | 118 | 132 |
| 2019 | 122 | 173 |
| 2020 | 142 | 178 |
| 2021 | 107 | 174 |
| 2022 | 101 | 150 |
| 2023 | 87 | 112 |
| 2024 | 78 | 100 |
| 2025 | 73 | 89 |
| 2026 | 40 | 64 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- MICA/B antibodies and methods of use29 Sep 2026US 12,747,293 B2Cullinan Mica Corporation
- Methods and antibody compositions for tumor treatment29 Sep 2026US 12,747,300 B2Regeneron Pharmaceuticals, Inc.
- Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use15 Sep 2026US 12,735,497 B2Hoffmann-La Roche Inc.
- Arginase 1 binders for inhibiting Arginase 1 activity15 Sep 2026US 12,735,506 B2Merck Sharp & Dohme Corp.
- Antibodies binding 4-1BB and uses thereof1 Sep 2026US 12,723,086 B2Nanjing Leads Biolabs Co., Ltd.
- Il-15 inhibitors useful for the treatment of atopic dermatitis1 Oct 2026US 2026/0297174 A1Novartis Pharma AG
- Methods and compositions comprising purified recombinant polypeptides1 Oct 2026US 2026/0297179 A1Genentech, Inc.
- Anti-HER2 Antibodies and Immunoconjugates1 Oct 2026US 2026/0297214 A1Genentech, Inc.
- Genetic engneering of b cell receptors and uses thereof in antigen-induced antibody secretion17 Sep 2026US 2026/0274916 A1Ramot at Tel-Aviv University Ltd.
- Multispecific antigen binding proteins and uses thereof10 Sep 2026US 2026/0265376 A1Itabmed Co., Ltd.
Most cited
By later US patents
- Cysteine engineered antibodies and conjugates485US 7,521,541 B2Genetech, Inc. · 2009
- Methods of modifying eukaryotic cells420US 6,596,541 B2Regeneron Pharmaceuticals, Inc. · 2003
- Dual variable domain immunoglobulin and uses thereof391US 7,612,181 B2Abbott Laboratories · 2009
- Humanization of murine antibody319US 7,087,409 B2The Scripps Research Institute · 2006
- Dual variable domain immunoglobulin and uses thereof187US 8,258,268 B2Abbott Laboratories · 2012